In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 6, 2005, Pages 3575-3582

  Van Wijk, J P H ^a   Castro Cabezas, M ^a,b   De Koning, E J P ^c   Rabelink, T J ^c   Van Der Geest, R ^c   Hoepelman, I M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; FATTY ACID; HYDROXYBUTYRIC ACID; TRIACYLGLYCEROL; LIPOPROTEIN;

ADIPOSE TISSUE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY FAT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FATTY ACID METABOLISM; FATTY ACID OXIDATION; HIV ASSOCIATED LIPODYSTROPHY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; ADOLESCENT; BLOOD; BODY MASS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METABOLISM; MIDDLE AGED; REFERENCE VALUE;

HUMAN IMMUNODEFICIENCY VIRUS;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FASTING; FATTY ACIDS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; REFERENCE VALUES; TOMOGRAPHY, X-RAY COMPUTED; TRIGLYCERIDES;

EID: 21244447474     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2343     Document Type: Article

References (39)

1. Carr A 2003 HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17(Suppl 1):S141-S148
2. Shevitz A, Wanke CA, Falutz J, Kotler DP 2001 Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS 15:1917-1930
3. Carr A, Cooper DA 2000 Adverse effects of antiretroviral therapy. Lancet 356:1423-1430
4. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs Study Group 2003 Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993-2003
5. Frayn KN 2002 Adipose tissue as a buffer for daily lipid flux. Diabetologia 45:1201-1210
6. Taskinen MR 2003 Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733-749
7. Miles JM, Haymond MW, Nissen SL, Gerich JE 1983 Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man. J Clin Invest 71:1554-1561
8. Meijssen S, Castro Cabezas M, Twickler TB, Jansen H, Erkelens DW 2000 In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res 41:1096-1102
9. Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, Havekes LM, Voshol PJ 2003 CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res 44:2270-2277
10. Cianflone K, Maslowska M, Sniderman AD 1999 Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin Cell Dev Biol 10:31-41
11. Sniderman AD, Cianflone K, Arner P, Summers LK, Frayn KN 1998 The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol 18:147-151
12. Scantlebury T, Maslowska M, Cianflone K 1998 Chylomicron-specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes. J Biol Chem 273:20903-20909
13. Verseyden C, Meijssen S, van Dijk H, Jansen H, Castro Cabezas M 2003 Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J Lipid Res 44:2100-2108
14. Halkes CJ, van Dijk H, de Jaegere PP, Plokker HW, van der Helm Y, Erkelens DW, Castro Cabezas M 2001 Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expandeddose simvastatin. Arterioscler Thromb Vasc Biol 21:1526-1530
15. Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Castro Cabezas M 2002 Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 22:811-816
16. van Oostrom AJ, van Dijk H, Verseyden C, Sniderman A, Cianflone K, Rabelink TJ, Castro Cabezas M 2004 Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial rise of complement component 3. Am J Clin Nutr 79:510-515
17. Ylitalo K, Porkka KV, Meri S, Nuotio I, Suurinkeroinen L, Vakkilainen J, Pajukanta P, Viikari JS, Peltonen L, Ehnholm C, Taskinen MR 1997 Serum complement and familial combined hyperlipidemia. Atherosclerosis 129:271-277
18. Kwiterovich Jr P, Motevalli M, Miller M 1990 Acylation-stimulatory activity in hyperapobetalipoproteinemic fibroblasts: enhanced cholesterol esterification with another serum basic protein, BP II. Proc Natl Acad Sci USA 87:8980-8984
19. Cianflone KM, Maslowska MH, Sniderman AD 1990 Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein. J Clin Invest 85:722-730
20. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG, HIV Lipodystrophy Case Definition Study Group 2003 An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361:726-735
21. Verseyden C, Meijssen S, Castro Cabezas M 2002 Postprandial changes of apoB-100 and apoB-48 in TG rich lipoproteins in familial combined hyperlipidemia. J Lipid Res 43:274-280
22. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE 1982 Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 36:172-177
23. Sekhar RV, Iyer D, Gaubatz J, Rehman K, Maldonado M, Pownall HJ, Visnegerwala F, Jahoor F, Balasubramanyam A 2003 Marked impairment of dietary triglyceride disposal contributes to hypertriglyceridemia in HIV lipodystrophy syndrome. Antiviral Ther 8:L46
24. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S 2002 Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 51:1143-1147
25. Reeds DN, Mittendorfer B, Patterson BW, Powderly WG, Yarasheski KE, Klein S 2003 Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol 285:E490-E497
26. Sekhar RV, Jahoor F, White AC, Pownall HJ, Visnegarwala F, Rodriguez-Barradas MC, Sharma M, Reeds PJ, Balasubramanyam A 2002 Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol 283:E332-E327
27. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M, Yki-Jarvinen H 2002 Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16:2183-2193
28. Mooser V, Carr A 2001 Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol 12:313-319
29. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, Sturley SL 2001 HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitorinduced hyperlipidemia. Nat Med 7:1327-1331
30. Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Humphreys SM, Kirk ML, Potts JL, Hockaday TD 1992 Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 41:264-272
31. Skowronski R, Hollenbeck CB, Varasteh BB, Chen Y-DI, Reaven GM 1991 Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with type 2 diabetes. Diabet Med 8:330-333
32. Ong JM, Kern PA 1989 Effect of feeding and obesity on lipoprotein lipase activity, immunoreactive protein, and messenger RNA levels in human adipose tissue. J Clin Invest 84:305-311
33. Kotler DP, Ionescu G, Johnson JA, Inada Y, He Q, Engelson ES, Albu JB 2003 Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis 37(Suppl 2):S47-S51
34. Weyer C, Tataranni PA, Pratley RE 2000 Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 23:779-785
35. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Drago G, Martignani C, Pacilli P, Boni P, Puddu P 2000 Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 21:1081-1090
36. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC 2000 Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquired Immune Defic Syndr 25:312-321
37. Meininger G, Hadigan C, Laposata M, Brown J, Rabe J, Louca J, Aliabadi N, Grinspoon S 2002 Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism 51:260-266
38. van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P, Sauerwein HP 2001 Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15:2093-2100
39. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, Gerich JE 2003 Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52:918-925